Piramal Pharma Q1 Results FY26: Q1 Loss Narrows 7.83% to ₹81.70 Crore; Revenue Fails 0.89% YoY

Piramal Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹1,933.71	₹1,951.14
Profit Before Tax (PBT)	₹165.10	₹224.03
Profit After Tax (PAT)	₹-81.70	₹-88.64

(Figures in crores)

Piramal Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹969.88	₹1,063.20
Profit Before Tax (PBT)	₹225.25	₹188.39
Profit After Tax (PAT)	₹113.14	₹85.27

(Figures in crores)

Piramal Pharma Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Piramal Pharma clocked Q1 FY26 consolidated revenue of ₹1,933.71 crores vs ₹1,951.14 crores. 
• On the profit front, Piramal Pharma's loss narrowed to ₹81.70 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹-88.64 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 7.83% YoY, and revenue fell 0.89% YoY. 
• As per the standalone figures, the quarterly PAT of Piramal Pharma has increased by 32.68% and revenue has decreased by 8.78% YoY.

Piramal Pharma Share Price Performance

On the opening bell of 29th July 2025, the shares of Piramal Pharma opened at ₹197.34 per share. However, the initial gains are wiped out as of now, and Piramal Pharma shares are trading at ₹203.51 per share, higher than their opening price. 

Considering the long-term performance, Piramal Pharma shares have yielded close to 20.51% returns in the past 1 year, and 5-year returns stand at 3.66%. Over the maximum timeframe, the  Piramal Pharma share provided 4.63% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Piramal Pharma shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Laxmi India Finance IPO GMP: Day 1 IPO Live Updates

Waaree Energies Q1 Results FY26: Q1 PAT Rose 89.07% to ₹745.20 Crore; Revenue Surged 29.83% YoY

Aditiya Infotech IPO GMP: Day 1 IPO Live Updates

Adani Green Q1 Results FY26: Q1 PAT Rose 59.87% to ₹713.00 Crore; Revenue Surged 36.01% YoY

Premier Energies Q1 Results FY26: Q1 PAT Rose 55.33% to ₹307.79 Crore; Revenue Surged 9.86% YoY

Ajanta Pharma Q1 Results FY26: Q1 PAT Rose 3.89% to ₹255.34 Crore; Revenue Surged 13.78% YoY